Dianthus Therapeutics, Inc.
DNTH
Rank in Stocks
#4060
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in... Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Share Price
$71.45
Last synced: 2026-10-16
Market Cap
$4.00B
Change (1 day)
-4.13%
Change (1 year)
100.42%
Country
US
Trade Dianthus Therapeutics, Inc. (DNTH)
Category
Healthcare
Number of shares outstanding for Dianthus Therapeutics, Inc. (DNTH)
Number of shares outstanding as of June 2026: 56.03M
According to Dianthus Therapeutics, Inc. latest financial reports and stock price the company's current number of shares outstanding is 56.03M. At the end of December 2023 the company had 5.15M shares outstanding. The number of outstanding shares is usually impacted by stock plits and shares buy back.
Shares outstanding history for Dianthus Therapeutics, Inc. (DNTH) from 2016 to 2026
Shares Outstanding at the end of each year
| Year | Shares Outstanding | Change |
|---|---|---|
| 2026 (TTM) | 56.03M | 68.18% |
| 2024 | 33.31M | 546.44% |
| 2023 | 5.15M | 37.53% |
| 2022 | 3.75M | 9.11% |
| 2021 | 3.43M | 25.11% |
| 2020 | 2.75M | 18.66% |
| 2019 | 2.31M | 11.11% |
| 2018 | 2.08M | -5.81% |
| 2017 | 2.21M | 0.00% |
| 2016 | 2.21M | 0.00% |
Shares Outstanding for similar companies or competitors
| Company | Shares Outstanding | Difference | Country |
|---|---|---|---|
| 253.90M | 353.16% |
US
|
|
| 396.00M | 606.78% |
US
|
|
| 478.91M | 754.76% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | 10.99% |
NL
|
